Axonal and neuronal degeneration in multiple sclerosis: Mechanisms and functional consequences

Current Opinion in Neurology

Volumn 14, Issue 3, 2001, Pages 271-278

  Bjartmar, Carl ^a   Trapp, Bruce D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXONAL INJURY; CELL STRUCTURE; DEMYELINATION; DISABILITY; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NERVE FIBER DEGENERATION; NERVE TRANSECTION; NUCLEAR MAGNETIC RESONANCE; PATIENT MONITORING; REVIEW;

ASPARTIC ACID; ATROPHY; AXONS; BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEURONS;

EID: 0034992601     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200106000-00003     Document Type: Review

References (58)

1. Multiple sclerosis
2. Axonal pathology in multiple sclerosis. A historical note
3. Histology of sclerotic plaques
4. Magnetic resonance imaging in the monitoring of disease progression in multiple sclerosis
5. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability
6. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis
7. Putting magnetic resonance spectroscopy studies in context: Axonal damage and disability in multiple sclerosis
8. Axonal damage in acute multiple sclerosis lesions
9. Axonal transection in the lesions of multiple sclerosis
10. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients
11. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin
12. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons
13. Axonal pathology in myelin disorders
14. Multiple sclerosis and chronic autoimmune encephalomyelitis. A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions
15. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation
16. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives
17. Glutamate excitotoxicity in a model of multiple sclerosis
18. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
19. A longitudinal study of brain atrophy in relapsing multiple sclerosis
20. A longitudinal study of T1 hypointense lesions in relapsing MS. MSCRG trial of interferon β-1a
21. Genetics of multiple sclerosis
22. Demyelinating diseases: New pathological insights, new therapeutic targets
23. Neurodegeneration in multiple sclerosis: Relationship to neurological disability
24. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis
25. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis
26. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions
27. Axonal changes in chronic demyelinated cervical spinal cord plaques
28. Relapses and progression of disability in multiple sclerosis
29. Correlating magnetic resonance imaging markers of axonal injury and demyelination in motor impairment secondary to stroke and multiple sclerosis
30. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss
31. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression
32. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study
33. The longstanding MS lesion
34. Spinal cord axonal loss in multiple sclerosis: A post-mortem study
35. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis
36. A Wallerian degeneration pattern in patients at risk for MS
37. Normal-appearing white matter changes in multiple sclerosis: The contribution of magnetic resonance techniques
38. Imaging axonal damage of normal-appearing white matter in multiple sclerosis
39. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study
40. Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis
41. Total brain N-acetylaspartate. A new measure of disease load in MS
42. The distribution of plaques in the cerebrum in multiple sclerosis
43. Cortical lesions in multiple sclerosis
44. Neuropathology of cortical lesions in multiple sclerosis
45. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction
46. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI)
47. Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS
48. Immunohistochemical localization of N-acetylaspartate in rat brain
49. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies
50. N-acetyl aspartate: A marker for neuronal loss or mitochondrial dysfunction
51. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro
52. In vitro expression of N-acetyl aspartate by oligodendrocytes: Implications for proton magnetic resonance spectroscopy signal in vivo
53. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo
54. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions
55. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis
56. Chemical pathology of acute demyelinating lesions and its correlation with disability
57. Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells
58. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis